Cutera (CUTR) Set to Announce Quarterly Earnings on Thursday

Cutera (NASDAQ:CUTR) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($1.06) per share for the quarter. Cutera has set its FY 2024 guidance at EPS.Parties that are interested in registering for the company’s conference call can do so using this link.

Cutera (NASDAQ:CUTR) last issued its earnings results on Thursday, March 21st. The medical device company reported ($2.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($1.07). The business had revenue of $49.54 million during the quarter, compared to the consensus estimate of $49.10 million. On average, analysts expect Cutera to post $-6 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cutera Stock Up 1.2 %

Shares of CUTR stock opened at $2.45 on Thursday. The business has a 50 day moving average of $1.98 and a two-hundred day moving average of $2.57. Cutera has a 52 week low of $1.28 and a 52 week high of $21.93. The company has a market cap of $48.85 million, a P/E ratio of -0.33 and a beta of 1.66.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on CUTR. William Blair raised Cutera from an “underperform” rating to a “market perform” rating in a report on Friday, March 22nd. Stephens reaffirmed an “overweight” rating and set a $10.00 price target on shares of Cutera in a report on Friday, March 22nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Cutera currently has a consensus rating of “Hold” and a consensus target price of $14.75.

Cutera Company Profile

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for deep dermal remodeling; truFlex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; and excel V+, a vascular and benign pigmented lesion treatment platform.